Cardiac amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:17:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cardiac amyloidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of [68Ga]Ga-FAPI-46 PET Imaging for Staging and Detecting Disease Progression in Patients with Transthyretin Cardiac Amyloidosis https://clinicaltrials.eu/trial/study-of-68ga-ga-fapi-46-pet-imaging-for-staging-and-detecting-disease-progression-in-patients-with-transthyretin-cardiac-amyloidosis/ Sat, 20 Jun 2026 04:04:45 +0000 https://clinicaltrials.eu/trial/study-of-68ga-ga-fapi-46-pet-imaging-for-staging-and-detecting-disease-progression-in-patients-with-transthyretin-cardiac-amyloidosis/ The study focuses on transthyretin cardiac amyloidosis, a condition where a misfolded protein called transthyretin builds up in the heart muscle and can make the heart work less efficiently. To look at the disease, participants will receive an injection of a special imaging substance called FAPI-46 (68Ga). This substance helps doctors see how much of the protein is affecting the heart when a scan is performed.

The purpose of the study is to find out whether this imaging test can accurately show how severe the heart involvement is. After the injection, a short‑lasting scan using PET technology will be done, which creates pictures of the heart by detecting the injected substance. Depending on the equipment available, the scan may be combined with either a CT scan (a type of X‑ray picture) or an MRI scan (a magnetic scan that shows detailed pictures of the heart).

Participants will be monitored for any immediate reactions right after the injection and then again a few minutes later. The imaging session lasts about one hour, during which the heart is photographed from different angles. All information gathered will be used only to understand how well the new imaging method works for this disease.

]]> A Study of Acoramidis in Adult Patients with Transthyretin Amyloidosis with Cardiomyopathy Who Previously Received Tafamidis https://clinicaltrials.eu/trial/a-study-of-acoramidis-in-adult-patients-with-transthyretin-amyloidosis-with-cardiomyopathy-who-previously-received-tafamidis/ Thu, 30 Apr 2026 13:08:35 +0000 https://clinicaltrials.eu/trial/a-study-of-acoramidis-in-adult-patients-with-transthyretin-amyloidosis-with-cardiomyopathy-who-previously-received-tafamidis/ This study involves people with transthyretin amyloid cardiomyopathy, a condition where an abnormal protein called transthyretin builds up in the heart muscle and causes the heart to work less effectively. The study will use a medication called acoramidis, which is also known by its code name BAY 3684938 and is marketed as BEYONTTRA. Participants in this study will be switching from another medication called tafamidis, which they have been taking for at least three months before joining the study. The purpose of this study is to measure how the levels of transthyretin protein in the blood change when people switch from tafamidis to acoramidis.

During the study, participants will take acoramidis as film-coated tablets by mouth. The study will last for six months, during which blood samples will be taken at different times to measure the amount of transthyretin protein and other substances in the blood. These measurements will be taken at the beginning of the study, then at week one, two, three, and four, and again at month three and month six. The study will also check how the heart is functioning using an ultrasound examination of the heart called ECHO, and will measure how far participants can walk in six minutes, which is called 6MWD. Other tests will look at kidney function, thyroid function, and various markers in the blood that can show how the heart and body are responding to the medication.

Throughout the study, doctors will monitor participants for any unwanted effects or health problems that may occur. The study will also use questionnaires to assess how participants feel and how the condition affects their daily life, including one called KCCQ-OS that focuses on heart-related quality of life and another called EQ-5D-5L that measures general health and wellbeing. Blood tests will check several markers including NT-proBNP, which indicates heart stress, hs-TnT, which shows heart muscle damage, hs-CRP, which measures inflammation, and RBP4, a protein that works with transthyretin. Additional blood tests will measure kidney function markers such as eGFR, creatinine, cystatin C, and UACR, as well as TSH, which checks thyroid function.

]]> A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy https://clinicaltrials.eu/trial/a-study-of-coramitug-compared-to-placebo-for-people-with-heart-failure-caused-by-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 15:08:43 +0000 https://clinicaltrials.eu/trial/a-study-of-coramitug-compared-to-placebo-for-people-with-heart-failure-caused-by-transthyretin-amyloid-cardiomyopathy/ This research study is looking at a condition called transthyretin amyloid cardiomyopathy, which is a disease where an abnormal protein called transthyretin builds up in the heart muscle and causes it to become stiff and not work properly. This buildup leads to heart failure, which means the heart cannot pump blood as well as it should, causing symptoms like shortness of breath, swelling in the legs, and tiredness. The disease can occur in two forms: one where the transthyretin protein is normal but still forms harmful deposits, and another where the protein has a genetic change that makes it more likely to form these deposits. The study will test a new medicine called coramitug, which is also known by its code name NNC6019-0001. This medicine is designed to target and remove the misfolded transthyretin protein that has built up in the heart. Participants in the study will receive either coramitug or placebo, both given in addition to their standard heart failure treatments.

The main goal of the study is to see if coramitug works better than placebo at reducing serious heart-related problems and deaths in people with this condition. During the study, participants will receive the study medicine through an intravenous infusion, which means it will be given directly into a vein. The treatment will continue for up to 192 weeks, which is about three and a half years. Throughout this time, doctors will monitor how well participants’ hearts are working, how far they can walk in six minutes, and how they feel in their daily lives using questionnaires about their symptoms and quality of life. The study will also track important events such as hospital visits for heart problems, worsening of heart failure requiring urgent medical care, and deaths related to heart and blood vessel problems.

To be eligible for this study, participants must have a confirmed diagnosis of transthyretin amyloid cardiomyopathy, which can be proven either through a heart tissue sample showing the abnormal protein deposits or through special imaging scans combined with other tests. They must have ongoing heart failure that requires treatment with water pills and must have either been hospitalized for heart failure at least once or have had clear signs of fluid buildup or heart pressure problems. Participants need to be on stable heart medications for at least four weeks before starting the study treatment, and they must have certain levels of a substance in their blood called NT-proBNP, which is a marker that shows how much strain the heart is under. They also need to be able to walk more than 50 meters during a walking test at the beginning of the study.

]]> Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) https://clinicaltrials.eu/trial/long-term-safety-study-of-nnc6019-0001-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ Wed, 29 Apr 2026 15:07:14 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-nnc6019-0001-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ This study focuses on people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal protein deposits build up in the heart muscle, leading to heart failure. The main treatment being studied is coramitug (also known as NNC6019-0001), which is given through an intravenous infusion. This medication is designed to target and remove the harmful protein deposits in the heart.

The purpose of this research is to evaluate how safe and effective long-term treatment with coramitug is for patients with ATTR-CM. During the study, participants will also receive standard medications for heart problems. The study will use various supportive medications including gadoteric acid as a contrast agent for imaging, paracetamol with codeine for pain relief, cetirizine for allergic reactions, and electrolyte solutions containing sodium chloride and other salts.

The study will last for 156 weeks (about 3 years). Throughout this time, participants will have regular check-ups to monitor their heart function and overall health. These check-ups will include various tests to measure heart performance and assess how well the treatment is working. The study will track any side effects that occur during the treatment period.

]]> Study on the Effects and Safety of Coramitug for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR CM) https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-coramitug-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ Wed, 29 Apr 2026 15:06:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-coramitug-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ This clinical trial is focused on studying a heart condition known as transthyretin amyloid cardiomyopathy (ATTR CM). This condition occurs when a protein called transthyretin misfolds and forms clumps in the heart, leading to heart disease. The study will test a new treatment called NNC6019-0001, also known as coramitug, which is a type of protein designed to target and help manage this condition. Participants in the study will receive either the new treatment or a placebo.

The purpose of the study is to evaluate how effective and safe the new treatment is for people with ATTR CM. The study will last for about a year, during which participants will receive the treatment through an intravenous infusion, meaning it will be administered directly into a vein. The study will monitor changes in participants’ ability to walk over six minutes and measure a heart-related protein called NT-proBNP to assess the treatment’s impact.

Throughout the study, participants will have regular check-ups to monitor their heart health and overall well-being. The study aims to provide valuable information on whether the new treatment can improve symptoms and quality of life for those with ATTR CM. Participants’ safety and any side effects will be closely observed to ensure the treatment is safe for use.

]]> Study on the Effects and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-alxn2220-for-adults-with-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 15:06:02 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-alxn2220-for-adults-with-transthyretin-amyloid-cardiomyopathy/ This clinical trial is focused on studying a heart condition known as Transthyretin Amyloid Cardiomyopathy (ATTR-CM). ATTR-CM is a disease where abnormal proteins, called amyloids, build up in the heart, affecting its function. The study will use a treatment called ALXN2220, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body, in this case, targeting the amyloids involved in ATTR-CM.

The purpose of this study is to evaluate how the body responds to re-treatment with ALXN2220 and to assess its safety in patients with ATTR-CM. Participants in the study will receive ALXN2220 as a solution for injection. The study will monitor changes in the heart using imaging techniques like cMRI (cardiac magnetic resonance imaging) and scintigraphy, which are methods to visualize the heart and assess its condition. The study will also track any side effects and changes in vital signs, such as blood pressure and heart rate, as well as laboratory test results and heart electrical activity through ECG (electrocardiogram).

Throughout the study, the levels of ALXN2220 in the blood will be measured, and any immune response to the medication will be monitored. The study aims to provide valuable information on the effectiveness and safety of ALXN2220 for patients with ATTR-CM, potentially leading to improved treatment options for this condition.

]]> Study on How Tafamidis is Absorbed in the Blood of Healthy Adults with Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-how-tafamidis-is-absorbed-in-the-blood-of-healthy-adults-with-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 15:05:31 +0000 https://clinicaltrials.eu/trial/study-on-how-tafamidis-is-absorbed-in-the-blood-of-healthy-adults-with-transthyretin-amyloid-cardiomyopathy/ This clinical trial is focused on studying how different forms of the study medicine, tafamidis, are absorbed into the blood in healthy adults. Tafamidis is a medication used to treat a heart condition known as transthyretin amyloid cardiomyopathy, which affects the heart’s ability to function properly. The study will compare the absorption of two different tablet forms of tafamidis (61 mg and 70 mg) to a capsule form (61 mg) when taken by healthy participants who have not eaten.

The purpose of the study is to estimate how well the body absorbs these different forms of tafamidis. Participants will receive a single dose of each form of the medication in a randomized order, meaning the order in which they receive the tablets and capsule will be determined by chance. The study will take place over three periods, with each participant receiving all three forms of the medication at different times. This approach helps researchers understand the differences in how the body takes up each form of the medication.

Throughout the study, participants will be monitored to measure the levels of tafamidis in their blood. This information will help determine the relative bioavailability, which is a term used to describe how much of the drug enters the bloodstream and is available to have an effect. The study is designed to ensure the safety and well-being of participants while providing valuable information about the medication’s absorption in the body.

]]> Study to Diagnose Cardiac Amyloidosis in Patients with Monoclonal Component Using Florbetaben (18F) PET-CT https://clinicaltrials.eu/trial/study-to-diagnose-cardiac-amyloidosis-in-patients-with-monoclonal-component-using-florbetaben-18f-pet-ct/ Wed, 29 Apr 2026 15:03:50 +0000 https://clinicaltrials.eu/trial/study-to-diagnose-cardiac-amyloidosis-in-patients-with-monoclonal-component-using-florbetaben-18f-pet-ct/ This clinical trial is focused on studying a condition known as cardiac amyloidosis, specifically a type called AL amyloidosis. This disease occurs when abnormal proteins, called amyloids, build up in the heart tissue, affecting its function. The study will use a special imaging technique called positron emission tomography/computed tomography (PET-CT) with a substance known as 18F-florbetaben. This technique helps to visualize the heart and detect amyloid deposits without needing invasive procedures.

The purpose of the study is to compare two methods of diagnosing AL amyloidosis: the traditional invasive method and a new non-invasive method using PET-CT with 18F-florbetaben. Participants will undergo the PET-CT scan, and the results will be compared to the traditional diagnostic approach to see how well the new method works. The study will also look at how the intensity of amyloid deposits changes over time and assess the safety of the PET-CT procedure.

Participants will receive an injection of Neuraceq, which contains 18F-florbetaben, and then undergo the PET-CT scan. The study will monitor participants for any side effects during and after the imaging procedure. The trial aims to provide a clearer, less invasive way to diagnose cardiac amyloidosis, potentially improving the diagnosis and management of this condition.

]]> Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease https://clinicaltrials.eu/trial/study-to-evaluate-the-safety-and-effectiveness-of-vutrisiran-in-patients-with-transthyretin-amyloidosis-and-heart-disease/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-to-evaluate-the-safety-and-effectiveness-of-vutrisiran-in-patients-with-transthyretin-amyloidosis-and-heart-disease/ This clinical trial is focused on studying a condition known as Transthyretin Amyloidosis with Cardiomyopathy, often referred to as ATTR Amyloidosis with Cardiomyopathy. This is a disease where abnormal proteins build up in the heart, affecting its function. The study will use a treatment called Vutrisiran, which is a solution for injection. Vutrisiran is also known by its code name ALN-TTRSC02. The purpose of the study is to gather information on the safety of Vutrisiran in patients who have this condition.

Participants in the study will receive Vutrisiran through an injection under the skin. The study will observe patients who are continuing their treatment with Vutrisiran or those who are switching from another medication called Patisiran. The study will last for a period of time, during which the safety of the treatment will be closely monitored. Patients will be asked to take vitamin A supplements as part of the study protocol.

The study will track how often any side effects occur and will also look at changes in heart-related health measures. These include changes in a questionnaire score that assesses heart failure symptoms, changes in heart function class, and levels of certain proteins in the blood that indicate heart stress. The study will also monitor overall survival and any heart-related hospital visits. The goal is to better understand how Vutrisiran affects patients with ATTR Amyloidosis with Cardiomyopathy over an extended period.

]]> Study on the Use of Flutemetamol (18F) for Diagnosing Cardiac Amyloidosis in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-flutemetamol-18f-for-diagnosing-cardiac-amyloidosis-in-patients/ Wed, 29 Apr 2026 15:01:57 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-flutemetamol-18f-for-diagnosing-cardiac-amyloidosis-in-patients/ This clinical trial is focused on studying cardiac amyloidosis, a condition where abnormal protein deposits, known as amyloid, build up in the heart tissue. The study will use a special imaging agent called Vizamyl, which contains the active substance Flutemetamol (18F). This agent is injected into the body and helps doctors see the amyloid deposits in the heart using a type of scan called PET (Positron Emission Tomography).

The purpose of the study is to evaluate how well Flutemetamol (18F) can detect amyloid deposits in patients with different types of cardiac amyloidosis, including ATTRwt, ATTRv, and AL. During the study, participants will receive an injection of Vizamyl and undergo a PET scan to measure the uptake of the tracer in the heart. This will help researchers understand how the tracer interacts with amyloid deposits and whether it can effectively identify the presence and extent of the disease.

The study will also compare the results in patients with different genetic types of cardiac amyloidosis and those with other heart conditions. By doing so, researchers aim to improve the diagnosis and understanding of cardiac amyloidosis, potentially leading to better treatment options in the future. Participants will be monitored throughout the study to ensure their safety and to gather valuable data on the effectiveness of the imaging agent.

]]> Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease https://clinicaltrials.eu/trial/study-of-patisiran-for-patients-with-transthyretin-amyloidosis-and-heart-disease/ Wed, 29 Apr 2026 15:01:53 +0000 https://clinicaltrials.eu/trial/study-of-patisiran-for-patients-with-transthyretin-amyloidosis-and-heart-disease/ This clinical trial is focused on studying a condition known as Transthyretin Amyloidosis with Cardiomyopathy, often referred to as ATTR Amyloidosis with Cardiomyopathy. This is a disease where abnormal proteins called amyloids build up in the heart, affecting its function. The study is evaluating a treatment called Patisiran, which is administered as a solution for infusion. Patisiran is designed to target and reduce the production of transthyretin, a protein that can misfold and form amyloid deposits in the heart.

The purpose of the study is to assess how effective and safe Patisiran is compared to a placebo in improving the ability to walk, as measured by a test called the 6-minute walk test. Participants in the study will receive either Patisiran or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for about 12 months, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will also look at other health outcomes, such as changes in symptoms and overall quality of life, using tools like the Kansas City Cardiomyopathy Questionnaire. The study aims to provide valuable information on whether Patisiran can help improve the lives of people with ATTR Amyloidosis with Cardiomyopathy by reducing symptoms and improving heart function.

]]> Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial https://clinicaltrials.eu/trial/study-on-the-safety-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-who-completed-a-previous-trial/ Wed, 29 Apr 2026 15:00:03 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-who-completed-a-previous-trial/ This clinical trial is focused on studying a condition known as Transthyretin Amyloid Cardiomyopathy (ATTR-CM). This is a heart disease where abnormal proteins build up in the heart, affecting its function. The study involves a treatment called Acoramidis (AG10), which is taken in tablet form. The purpose of the study is to monitor the safety and how well patients tolerate this medication.

Participants in this study are those who have already completed a previous trial involving the same medication. During the study, participants will continue to take Acoramidis and will be regularly monitored for any side effects or changes in their health. This includes checking for any serious health events, changes in physical exams, vital signs, and heart tests like electrocardiograms (ECG). The study will also look at overall health outcomes, such as any changes in walking distance and heart-related hospital visits.

The study aims to provide valuable information on the long-term safety of Acoramidis for people with ATTR-CM. It will help understand how the medication affects the heart and overall health over time. Participants will be closely observed to ensure their safety and to gather data that could benefit future patients with this condition.

]]> Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-eplontersen-for-patients-with-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm/ Wed, 29 Apr 2026 14:59:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-eplontersen-for-patients-with-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm/ This clinical trial is focused on studying a condition called Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). ATTR-CM is a heart disease where abnormal proteins build up in the heart, affecting its function. The study will test a treatment called ION-682884, also known as Eplontersen, which is a type of medication called an antisense oligonucleotide. This medication is designed to target and reduce the production of the abnormal protein causing the disease. Participants in the study will receive either the ION-682884 treatment or a placebo, which is an inactive substance that looks like the treatment but does not contain the active medication.

The purpose of the study is to evaluate the effect of ION-682884 on heart-related health outcomes in patients with ATTR-CM. Participants will receive regular injections under the skin and will be monitored over a period of time to assess the treatment’s impact on their heart health. The study will compare the number of heart-related events, such as heart failure or heart attacks, between those receiving the treatment and those receiving the placebo. The study aims to determine if ION-682884 can improve the health and quality of life for people with ATTR-CM.

Throughout the study, participants will continue to receive their usual care for ATTR-CM. The study will involve regular visits to the clinic for health assessments and to receive the injections. The overall goal is to see if ION-682884 can reduce the risk of serious heart problems and improve the well-being of patients with this condition. Participants’ health and safety will be closely monitored by the study team throughout the trial.

]]> Study on Heart Amyloidosis Using Sodium Fluoride (18F) and Iodine (123I) Iobenguane for Patients with Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-heart-amyloidosis-using-sodium-fluoride-18f-and-iodine-123i-iobenguane-for-patients-with-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 14:59:18 +0000 https://clinicaltrials.eu/trial/study-on-heart-amyloidosis-using-sodium-fluoride-18f-and-iodine-123i-iobenguane-for-patients-with-transthyretin-amyloid-cardiomyopathy/ This clinical trial is focused on studying a heart condition known as transthyretin amyloid cardiomyopathy, which affects the heart’s ability to function properly. The study will use two different treatments: sodium fluoride (18F) and iodine (123I) iobenguane. These treatments are given as a solution for injection, meaning they are administered directly into the bloodstream through an injection.

The purpose of the study is to understand how these treatments can help in measuring certain changes in the heart. Participants will undergo imaging tests, such as PET/CT scans, to see how the heart is affected by the disease and the treatments. The study will also look at how the heart’s function changes over time, especially in terms of how it handles calcium deposits and nerve signals.

Throughout the study, participants will have regular check-ups and imaging tests to monitor their heart health. The study will last for about a year, and during this time, researchers will collect data to better understand the effects of the treatments on heart function and overall health. This information could help improve future treatments for people with transthyretin amyloid cardiomyopathy.

]]> Study on the Effects of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis https://clinicaltrials.eu/trial/study-on-the-effects-of-tafamidis-in-patients-with-transthyretin-cardiac-amyloidosis/ Wed, 29 Apr 2026 14:58:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-tafamidis-in-patients-with-transthyretin-cardiac-amyloidosis/ This clinical trial is focused on studying a condition known as transthyretin cardiac amyloidosis, a disease where abnormal proteins build up in the heart, affecting its function. The treatment being tested is a medication called tafamidis, also known by its code name FX-1006. Tafamidis is provided in the form of soft capsules and is taken orally. The purpose of the study is to observe changes in the heart using magnetic resonance imaging (MRI) before and after treatment with tafamidis over a period of 12 months.

Participants in the study will receive either tafamidis or a placebo. Throughout the study, the heart’s structure and function will be monitored using MRI to assess any changes. The study will also track the frequency of hospitalizations related to heart failure and overall survival rates. Additionally, changes in heart-related symptoms and physical activity levels will be evaluated using questionnaires and walking tests.

The study aims to provide a better understanding of how tafamidis affects the heart in patients with transthyretin cardiac amyloidosis. By comparing MRI results and other health indicators before and after treatment, researchers hope to gain insights into the potential benefits of tafamidis for managing this condition.

]]> Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease https://clinicaltrials.eu/trial/study-of-vutrisiran-for-patients-with-transthyretin-amyloidosis-and-heart-disease/ Wed, 29 Apr 2026 14:57:39 +0000 https://clinicaltrials.eu/trial/study-of-vutrisiran-for-patients-with-transthyretin-amyloidosis-and-heart-disease/ This clinical trial is focused on studying a condition known as Transthyretin Amyloidosis with Cardiomyopathy. This is a disease where abnormal proteins called amyloids build up in the heart, leading to heart problems. The study is testing a treatment called Vutrisiran, which is given as an injection under the skin. Vutrisiran is a type of medicine that belongs to a group known as nucleic acids, which are designed to target and reduce the production of these harmful proteins in the body.

The purpose of the study is to evaluate how effective Vutrisiran is compared to a placebo in reducing deaths from any cause and heart-related events, such as hospital visits due to heart problems. Participants in the study will receive either Vutrisiran or a placebo and will be monitored over a period of time to see how their condition changes. The study will also look at how Vutrisiran affects the ability to walk over a short distance, quality of life related to heart health, and overall health status.

Throughout the study, participants will undergo regular check-ups and assessments to track their health and any changes in their condition. The study aims to provide valuable information on whether Vutrisiran can be a safe and effective treatment option for people with Transthyretin Amyloidosis with Cardiomyopathy. This research could potentially lead to better management and outcomes for those affected by this challenging condition.

]]> Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-alxn2220-for-adults-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ Wed, 29 Apr 2026 14:30:12 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-alxn2220-for-adults-with-transthyretin-amyloid-cardiomyopathy-attr-cm/ This clinical trial is focused on studying a condition known as Transthyretin Amyloid Cardiomyopathy (ATTR-CM). ATTR-CM is a heart disease caused by the buildup of abnormal proteins called amyloids in the heart tissue, which can lead to heart failure. The study is testing a new treatment called ALXN2220, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body, in this case, the amyloid proteins, to help remove them.

The purpose of this study is to evaluate the effectiveness and safety of ALXN2220 in adults with ATTR-CM. Participants in the study will receive either the ALXN2220 treatment or a placebo, which is a substance with no active medication. The study will be conducted over a period of time, during which participants will receive regular injections of the treatment or placebo. Throughout the study, participants will be monitored for any changes in their heart condition and overall health.

The study aims to determine if ALXN2220 can help reduce the symptoms and progression of ATTR-CM by comparing the health outcomes of those receiving the treatment to those receiving the placebo. Participants will undergo various health assessments, including heart function tests and physical examinations, to track their progress. The study will provide valuable information on whether ALXN2220 is a safe and effective treatment option for people with ATTR-CM.

]]> Long-Term Safety Study of NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy or Transthyretin Amyloidosis-Related Cardiomyopathy https://clinicaltrials.eu/trial/long-term-safety-study-of-ntla-2001-for-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy-or-transthyretin-amyloidosis-related-cardiomyopathy/ Wed, 29 Apr 2026 14:30:08 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-ntla-2001-for-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy-or-transthyretin-amyloidosis-related-cardiomyopathy/ This clinical trial is focused on the long-term follow-up of individuals who have been treated with a medication called NTLA-2001. The study is specifically looking at two conditions: Hereditary Transthyretin Amyloidosis with Polyneuropathy and Transthyretin Amyloidosis-Related Cardiomyopathy. These are rare diseases where abnormal proteins build up in the body, affecting nerves and the heart. The treatment, NTLA-2001, is a type of gene therapy designed to target and modify the Transthyretin (TTR) gene, which is involved in these conditions.

The purpose of this study is to evaluate the long-term safety of NTLA-2001 in participants who have already received this treatment in previous studies. Participants will be monitored over time to check for any side effects related to the treatment and to observe specific health markers. The study involves regular follow-up visits where participants’ health will be assessed, but it does not involve any new treatments or medications beyond what they have already received.

Participants in this study have previously completed or discontinued a clinical study involving NTLA-2001 and have agreed to continue with follow-up visits. The study aims to gather important information about the long-term effects of the treatment, which will help in understanding its safety and impact on the conditions being studied. This information is crucial for developing future treatments and improving care for individuals with these rare diseases.

]]> Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-drug-combination-for-patients-with-advanced-al-amyloidosis/ Wed, 29 Apr 2026 14:29:33 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-drug-combination-for-patients-with-advanced-al-amyloidosis/ This clinical trial is focused on studying a condition called AL amyloidosis, specifically in patients with a severe form known as Stage IIIb cardiac AL amyloidosis. This disease involves the buildup of abnormal proteins in the heart, which can lead to heart problems. The study is testing a new treatment called CAEL-101, also known by its code name anselamimab. This treatment is being compared to a placebo, which is a substance with no active medication, to see if it can improve the survival of patients who have not received any previous treatment for this condition.

Participants in the study will receive either the new treatment or a placebo, along with standard treatments for a related condition called plasma cell dyscrasia. The standard treatments include medications such as cyclophosphamide, bortezomib, and dexamethasone. These medications are commonly used to treat disorders involving abnormal plasma cells, which are a type of white blood cell. The study aims to determine if the combination of CAEL-101 and these standard treatments can help patients live longer and improve their quality of life.

The study will be conducted over a period of time, during which participants will receive their assigned treatments and be monitored for any changes in their health. The main goal is to assess the time it takes for any cause of death to occur from the start of the study. Additionally, the study will look at other health measures, such as heart function and physical activity levels, to evaluate the overall effectiveness and safety of the new treatment. Participants will be closely observed to ensure their safety throughout the study.

]]> Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vutrisiran-and-patisiran-for-patients-with-hereditary-transthyretin-amyloidosis/ Wed, 29 Apr 2026 14:28:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vutrisiran-and-patisiran-for-patients-with-hereditary-transthyretin-amyloidosis/ This clinical trial is focused on studying a condition known as Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). This is a rare genetic disease where abnormal proteins build up in the body, leading to nerve damage and other health issues. The study is evaluating a treatment called ALN-TTRSC02, which is also known by its code name. This treatment is designed to help reduce the effects of the disease on the nervous system.

The purpose of the study is to assess how effective and safe ALN-TTRSC02 is for patients with hATTR Amyloidosis. Participants in the study will receive the treatment as a solution for injection. The study will also compare the effects of ALN-TTRSC02 with another treatment called Onpattro, which is given as a solution for infusion. Some participants may receive a placebo instead of the active treatment. The study will monitor changes in nerve function and quality of life over time.

Throughout the study, participants will undergo regular assessments to track their progress and any changes in their condition. The study aims to provide valuable information on how ALN-TTRSC02 can help manage the symptoms of hATTR Amyloidosis and improve the lives of those affected by this condition.

]]> Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-plasma-cell-dyscrasia-treatment-in-patients-with-stage-iiia-al-amyloidosis/ Wed, 29 Apr 2026 14:28:26 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-plasma-cell-dyscrasia-treatment-in-patients-with-stage-iiia-al-amyloidosis/ This clinical trial is focused on studying a condition called AL amyloidosis, specifically in patients with a severe form known as stage IIIa cardiac AL amyloidosis. This disease involves the buildup of abnormal proteins in organs and tissues, which can affect the heart. The study is testing a new treatment called CAEL-101, which is given as a solution through an intravenous infusion. The trial will compare the effects of CAEL-101 combined with standard treatment for a related condition called plasma cell dyscrasia against a placebo combined with the same standard treatment.

The purpose of the study is to see if CAEL-101 can help improve the survival of patients who have not yet received treatment for their condition. The study will also look at how safe and tolerable CAEL-101 is when used with the standard treatment. Participants will receive either the new treatment or a placebo, along with their regular therapy, and will be monitored over time to assess their health and any changes in their condition.

Throughout the study, participants will undergo various health checks, including monitoring of vital signs and heart function, to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential benefits of CAEL-101 for patients with this challenging disease.

]]> Study on the Effects of Dobutamine on Heart Function in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-the-effects-of-dobutamine-on-heart-function-in-patients-with-wild-type-transthyretin-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 14:25:48 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-dobutamine-on-heart-function-in-patients-with-wild-type-transthyretin-amyloid-cardiomyopathy/ This clinical trial is focused on studying the effects of a medication called Dobutamine in patients with a heart condition known as Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). This condition affects the heart’s ability to pump blood effectively. The study aims to understand how different doses of Dobutamine can impact heart function and to ensure the safety of this treatment in patients with ATTRwt.

During the trial, participants will receive Dobutamine through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will also use other solutions like Glukose Isotonisk and Sodium Chloride to support the treatment process. The trial will monitor changes in heart function using methods like right heart catheterization and echocardiography, which are techniques to assess how well the heart is working.

The study will take place over a period, with the goal of observing any improvements in heart function, such as increased cardiac output and stroke volume, as well as any potential side effects. The results will help determine the effectiveness and safety of Dobutamine for patients with ATTRwt, providing valuable insights into managing this heart condition.

]]> Study on the Use of Florbetaben (18F) PET Imaging for Diagnosing Cardiac AL Amyloidosis in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-florbetaben-18f-pet-imaging-for-diagnosing-cardiac-al-amyloidosis-in-patients/ Wed, 29 Apr 2026 14:25:14 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-florbetaben-18f-pet-imaging-for-diagnosing-cardiac-al-amyloidosis-in-patients/ This clinical trial is focused on studying a condition known as Cardiac Amyloidosis, which is a heart-related disease caused by the buildup of abnormal proteins called amyloids in the heart tissue. The study also includes a specific type of this condition called AL Amyloidosis. The trial will use a special imaging technique called Positron Emission Tomography (PET) with a substance known as [18F]florbetaben. This substance is injected into the body and helps to create detailed images of the heart, which can assist doctors in diagnosing the disease.

The purpose of the study is to evaluate how effective and safe the [18F]florbetaben PET imaging is in diagnosing Cardiac AL Amyloidosis. Participants in the study will undergo this imaging process, which involves receiving an injection of the [18F]florbetaben solution. The study aims to determine how accurately this imaging method can identify the presence of the disease compared to the standard clinical diagnosis methods currently in use.

Throughout the study, participants will have their heart images taken using the PET scan, and these images will be visually assessed by medical professionals. The study will also explore how the results from the PET scans correlate with other heart function measurements, such as the heart’s pumping ability and the size of the heart muscle. The findings from this study could potentially improve the way Cardiac Amyloidosis is diagnosed and managed in the future.

]]> Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy https://clinicaltrials.eu/trial/study-on-long-term-safety-of-eplontersen-for-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/ Wed, 29 Apr 2026 14:24:14 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-eplontersen-for-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/ This clinical trial is focused on studying a condition known as Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). This is a heart condition where abnormal proteins build up in the heart, affecting its function. The study will use a treatment called Eplontersen, which is also known by its code name ION 682884. Eplontersen is a type of medication called an antisense oligonucleotide, which is designed to target and reduce the production of specific proteins in the body. The purpose of this study is to evaluate the long-term safety of Eplontersen in patients with ATTR-CM.

Participants in the study will receive Eplontersen through a subcutaneous injection, which means it is injected under the skin. The study will also involve taking Concavit Capsules, which contain a combination of vitamins such as Vitamin A and Ascorbic Acid (Vitamin C). These capsules are taken orally, meaning they are swallowed. The study will last for a period of up to 36 months, during which participants will be monitored regularly to assess the safety and tolerability of the treatment. This includes checking various health indicators through blood tests and other clinical assessments.

The study aims to gather information on how the treatment affects the body over time, including any side effects or changes in health status. Participants will be asked to complete questionnaires about their quality of life and undergo tests to measure heart function and other health markers. The results of this study will help determine the long-term safety of Eplontersen for people with ATTR-CM.

]]> Study on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis https://clinicaltrials.eu/trial/study-on-the-impact-of-dapagliflozin-on-quality-of-life-and-exercise-capacity-in-patients-with-transthyretin-cardiac-amyloidosis/ Wed, 29 Apr 2026 14:24:05 +0000 https://clinicaltrials.eu/trial/study-on-the-impact-of-dapagliflozin-on-quality-of-life-and-exercise-capacity-in-patients-with-transthyretin-cardiac-amyloidosis/ This clinical trial is focused on studying the effects of a medication called dapagliflozin on patients with a heart condition known as amyloid transthyretin cardiac amyloidosis (ATTR-CA). ATTR-CA is a disease where abnormal protein deposits, called amyloids, build up in the heart, affecting its function. The medication being tested, dapagliflozin, is taken as a film-coated tablet and is commonly used to treat other conditions like diabetes. In this study, researchers aim to understand how dapagliflozin affects the quality of life and exercise capacity of people with ATTR-CA.

The purpose of the study is to determine the impact of dapagliflozin on the ability of patients with ATTR-CA to exercise. Participants in the study will be given either dapagliflozin or a placebo, and their progress will be monitored over a period of time. The study will look at changes in how far patients can walk in six minutes, which is a common way to measure exercise capacity. Additionally, researchers will assess improvements in patients’ overall well-being and any changes in heart-related symptoms.

Throughout the study, the safety of dapagliflozin will be closely monitored by recording any side effects experienced by participants. The study will also evaluate if there are any changes in the use of other heart medications, such as diuretics, which help remove excess fluid from the body. By the end of the study, researchers hope to gather valuable information on how dapagliflozin can benefit patients with ATTR-CA, potentially leading to better treatment options in the future.

]]> Study on the Effects of Valsartan and Sacubitril for Patients with Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction https://clinicaltrials.eu/trial/study-on-the-effects-of-valsartan-and-sacubitril-for-patients-with-transthyretin-cardiac-amyloidosis-and-heart-failure-with-reduced-ejection-fraction/ Wed, 29 Apr 2026 14:22:42 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-valsartan-and-sacubitril-for-patients-with-transthyretin-cardiac-amyloidosis-and-heart-failure-with-reduced-ejection-fraction/ This clinical trial is focused on studying the effects of a medication called Entresto, which contains the active substances valsartan and sacubitril, on two heart conditions: transthyretin cardiac amyloidosis and heart failure with reduced ejection fraction. Transthyretin cardiac amyloidosis is a condition where abnormal proteins build up in the heart, affecting its function. Heart failure with reduced ejection fraction is a type of heart failure where the heart does not pump blood as well as it should.

The purpose of this study is to determine how treatment with Entresto affects the heart’s ability to pump blood in patients with these conditions. Participants in the study will receive either Entresto or a placebo, and their heart function will be monitored over a period of 12 months. The main focus will be on changes in the heart’s pumping ability, measured by a test called an echocardiogram, which uses sound waves to create images of the heart.

Throughout the study, participants will undergo regular check-ups and echocardiograms to assess any changes in their heart function. The goal is to see if there is an improvement in the heart’s pumping ability after 12 months of treatment with Entresto compared to those who do not receive the medication. This research aims to provide valuable insights into the potential benefits of Entresto for patients with these specific heart conditions.

]]>